Horizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209
|
|
- Camron Singleton
- 5 years ago
- Views:
Transcription
1 Horizon Scanning Centre March 2015 Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209 This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. Ixekizumab is intended for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy. If licensed, ixekizumab will offer an additional treatment option for this patient group. Treatment with ixekizumab may result in some patients achieving near/full clearance of psoriasis symptoms. Ixekizumab is a humanised immunoglobulin G subclass 4 (IgG4) monoclonal antibody that neutralises interleukin-17a (IL-17), which is a key T cell-derived cytokine involved in inducing and mediating inflammation. It does not currently have Marketing Authorisation in the EU for any indication. The prevalence of psoriasis in England is estimated to be around 1.63%, equating to around 900,000 people with the condition. Plaque psoriasis accounts for around 90% of cases and approximately 20% have moderate to severe psoriasis (15% moderate, 5% severe). The estimated prevalence of people currently eligible for biological therapy in England is 3% of those with psoriasis, equating to around 27,000 people. However, because of the nature of the condition, not all patients eligible for biologic treatments will currently be identified and/or treated with these agents. In , there were 1,454 hospital admissions in England as a result of psoriasis vulgaris, equating to 1,537 finished consultant episodes and 3,912 bed days. Thirty deaths from psoriasis were registered in England and Wales during Treatment options for psoriasis aim to reduce symptoms and improve patient quality of life. Topical treatments are usually offered as first line therapy, followed by phototherapy and/or systemic therapies as second line treatment, and biological therapies as third line treatment regimes. Ixekizumab is currently in three phase III clinical trials comparing its effect on the Psoriasis Area Severity Index (PASI) against treatment with etanercept and placebo. These trials are expected to be completed by This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. NIHR Horizon Scanning Centre, University of Birmingham nihrhsc@contacts.bham.ac.uk Web:
2 TARGET GROUP Plaque psoriasis: moderate to severe; chronic adults who are candidates for systemic therapies. TECHNOLOGY DESCRIPTION Ixekizumb (LY , anti-il-17 monoclonal antibody) is a humanised immunoglobulin G subclass 4 (IgG4) monoclonal antibody that neutralises interleukin-17a (IL-17), which is a key T cell-derived cytokine involved in inducing and mediating inflammation. Ixekizumab is intended for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy. It is administered subcutaneously (SC) at a frequency and dose to be determined from the company s phase III trial 1. The company anticipate that the dosing regimen will consist of a 160mg initial dose, followed by 80mg dosing through the induction and maintenance periods. Ixekizumab does not currently have Marketing Authorisation in the EU for any indication. Ixekizumab is also in phase III clinical trials for psoriatic arthritis; and phase II for rheumatoid arthritis. INNOVATION and/or ADVANTAGES If licensed, ixekizumab will offer an additional treatment option for patients with moderate to severe plaque psoriasis who are candidates for systemic therapy. Treatment with ixekizumab may result in some patients achieving near/full clearance of psoriasis symptoms. DEVELOPER Eli Lilly and Company Limited. AVAILABILITY, LAUNCH OR MARKETING In phase III clinical trials. PATIENT GROUP BACKGROUND Psoriasis is an inflammatory skin condition characterised by well-defined, sharply demarcated, erythematous plaques, which can be one centimetre to several centimetres in size. Plaques may form across specific areas such as the scalp, trunk, limbs, buttocks, elbows and knees, but can also manifest across the entire body causing pain and pruritus. Plaques appear as dry, thin, silvery-white scales, and often smaller plaques merge forming larger plaques, particularly over the leg and trunk 2,3. The cause of psoriasis is not known although genetics, the environment, and an overactive immune system (in particular T cells) are thought to play a part 4. Psoriasis typically follows a relapsing and remitting course, with flare ups occurring spontaneously 5. Contributors to flare ups include stress, infections, medications, sunlight, trauma, hormonal changes, smoking and alcohol 3. 2
3 Patients with psoriasis often experience feelings of self-consciousness and embarrassment, and as a result, may suffer unemployment, social isolation, and depression; all factors which contribute to a reduction in overall patient quality of life 6. The adverse psychosocial issues associated with the condition also contribute to worsening outcomes for patients with psoriasis 7. NHS or GOVERNMENT PRIORITY AREA This topic is relevant to: Department of Health. Improving quality of life for people with long term conditions (2013). NHS England NHS Standard Contract for Specialised Dermatology Services (All ages). A12/S/a. CLINICAL NEED and BURDEN OF DISEASE The prevalence of psoriasis in England is estimated to be around 1.63%, equating to approximately 900,000 people with the condition 8,a. Plaque psoriasis accounts for around 90% of cases and approximately 20% have moderate to severe disease (15% moderate, 5% severe) 8. Onset may occur at any age, although it is uncommon in children (prevalence 0.71%), with the majority of cases occurring before the age of 35. Life expectancy in men and women with severe psoriasis is reduced by 3.5 and 4.4 years respectively 9, primarily due to metabolic syndrome and heart disease 10. Females typically develop plaque psoriasis earlier than males, and patients with a positive family history for psoriasis also tend to have an earlier age of onset 12. Acute flares or relapses of plaque psoriasis may evolve into more severe disease, such as pustular or erythrodermic psoriasis 5. The estimated prevalence of people currently eligible for biological therapy in England is 3% 11 of those with psoriasis, equating to around 27,000 people. However, because of the nature of the condition, not all patients eligible for biologic treatments will currently be identified and/or treated with these agents 11. In , there were 1,454 hospital admissions in England as a result of psoriasis vulgaris (ICD-10 L40.0), equating to 1,537 finished consultant episodes and 3,912 bed days 12. Thirty deaths from psoriasis were registered in England and Wales during 2013 (ICD-10 L40) 13. PATIENT PATHWAY RELEVANT GUIDANCE NICE Guidance NICE technology appraisal in development. Psoriasis (plaque, moderate to severe) - apremilast [ID679]. Expected August NICE technology appraisal in development. Secukinumab for treating moderate to severe plaque psoriasis [ID718]. Expected July NICE technology appraisal. Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180). September a Based on Office for National Statistics mid-2013 population estimate for England. 3
4 NICE technology appraisal. Adalimumab for the treatment of adults with psoriasis (TA146). June NICE technology appraisal. Infliximab for the treatment of adults with psoriasis (TA134). January NICE technology appraisal. Etanercept and efalizumab for the treatment of adults with psoriasis (TA103). July NICE clinical guideline. Psoriasis: The assessment and management of psoriasis (CG153). October NICE quality standard. Psoriasis (QS40). August NICE interventional procedure guidance. Grenz rays therapy for inflammatory skin conditions (IPG236). November Other Guidance Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults (121) British Association of Dermatologists and Primary Care Dermatology Society. Clinical guideline: Recommendations for the initial management of psoriasis British Association of Dermatologists. Guidelines for biologic interventions for psoriasis CURRENT TREATMENT OPTIONS Treatment options for psoriasis aim to reduce symptoms and improve patient quality of life. Topical treatments are usually offered as first line therapy, followed by phototherapy and/or systemic therapies as second line treatment, and biological therapies as third line treatment regimes. The majority of psoriasis cases are managed at the primary care level, though up to 60% of patients may require referral to a specialist 5. Current treatment options for plaque psoriasis include 16,17,18,19 : Topical (alone or in combination) Emollients. Corticosteroids: e.g. betamethasone dipropionate. Vitamin D analogues: calcipotriol, calcitriol, tacalcitol (with or without phototherapy). Tars (with or without phototherapy). Dithranol (with or without phototherapy). Retinoids: tazarotene. Salicyclic acid. Tacrolimus ointment (not licensed for this indication). Phototherapy Broad- or narrow-band UVB and psoralen and UVA combination (PUVA). Systemic conventional disease modifying therapies (for the treatment of patients with moderate to severe or refractory psoriasis) Oral retinoids: acitretin (with or without phototherapy). Hydroxycarbamide (not licensed for this indication). Ciclosporin. Methotrexate. 4
5 Apremilast. Biological therapies (for the treatment of patients with moderate to severe psoriasis who are candidates for systemic therapies) Secukinumab (IL-17A inhibitor). Biological therapies (for the treatment of patients intolerant, contraindicated or refractory to other systemic conventional disease modifying treatments and/or phototherapy) Adalimumab (TNF- Etanercept (TNF-nhibitor). Infliximab (TNF- Ustekinumab (IL-12 and IL-23 inhibitor). EFFICACY and SAFETY Trial UNCOVER-1, NCT , 12972, I1F-MC-RHAZ; ixekizumab vs placebo; phase III. UNCOVER-2, NCT , 12973, I1F-MC-RHBA; ixekizumab vs etanercept vs placebo; phase III. UNCOVER-3, NCT , 13685, I1F-MC-RHBC; ixekizumab vs etanercept vs placebo; phase III. Sponsor Eli Lilly and Company. Eli Lilly and Company. Eli Lilly and Company. Status Ongoing. Ongoing. Ongoing. Source of information Trials registry 1, press release 20. Trial registry 21, press release 24. Trial registry 22, press release 24. Location Design Participants Schedule EU (incl UK), USA, Canada and other countries. Randomised, placebocontrolled. n=1,296; aged 18 years and older; plaque psoriasis (at least 10% of body surface area); chronic; moderate to severe; spga b score of at least 3 and PASI c score of at least 12 at screening and at first dose of study drug; candidate for phototherapy and/or systemic therapy. Induction period (up to week 12): EU (incl UK), USA, Canada and other countries. Randomised, active- and placebo- controlled. n=1,224; aged 18 years and older; plaque psoriasis (at least 10% of body surface area); chronic; moderate to severe; spga score of at least 3 and PASI score of at least 12 at screening and at first dose of study drug; candidate for phototherapy and/or systemic therapy. Induction period (up to week 12): EU, USA, Canada and other countries. Randomised, active- and placebo- controlled. n=1,346; aged 18 years and older; plaque psoriasis (at least 10% of body surface area); chronic; spga score of at least 3 and PASI score of at least 12 at screening and at randomisation; candidate for phototherapy and/or systemic therapy. Induction period (up to week 12): Randomised to: Arm 1: ixekizumab 160mg SC injection at week 0, then ixekizumab 80mg once every two weeks for 12 At week 12, responders (spga 0 or 1) to treatment are re- Randomised to: Arm 1: ixekizumab 160mg SC injection at week 0, then ixekizumab 80mg once every two weeks for 12 At week 12, responders to treatment are re-randomised to Randomised to: Arm 1: ixekizumab 160mg SC injection at week 0, then ixekizumab 80mg once every two weeks for 12 At week 12, patients are assigned to dosing regimen 2. b The static PGA (spga) measures the physician s impression of the disease (psoriasis). c PASI (Psoriasis Area Severity Index) is an index used to express the severity of psoriasis. It combines severity (erythema, induration and desquamation) and percentage of affected body surface area. 5
6 Follow-up randomised to placebo, dosing regimen 2 or dosing regimen 3. Arm 2: ixekizumab 160mg SC injection at week 0, then ixekizumab 80mg once every four weeks for 12 At week 12, responders to treatment are re-randomised to placebo, dosing regimen 2 or dosing regimen 3. Placebo: placebo SC injection at week 0, then once every two weeks for 12 At week 12, placebo non-responders receive starting dose of ixekizumab 160mg SC, followed by ixekizumab 80mg SC every 4 weeks for 48 Placebo responders remain on placebo SC every 4 weeks until relapse whereupon patients are placed on every 4 Maintenance dosing period: Randomised to: Placebo: placebo SC every 4 weeks for 48 Dosing regimen 2: every 4 weeks for 48 Dosing regimen 3: every 12 weeks for 48 Non-responders (spga >1) at week 12 and patients who relapsed every 4 Induction plus maintenance treatment period up to 60 placebo, dosing regimen 2 or dosing regimen 3. Arm 2: ixekizumab 160mg SC at week 0, then ixekizumab 80mg once every four weeks for 12 At week 12, responders to treatment are re-randomised to placebo, dosing regimen 2 or dosing regimen 3. Arm 3: etanercept 50mg SC twice weekly for 12 At week 12, responders to treatment receive placebo every 4 weeks until relapse. Patients who relapse on placebo receive every 4 Placebo: placebo for ixekizumab SC at week 0, then once every two weeks for 12 Placebo for etanercept SC twice weekly for 12 At week 12, nonresponders to placebo receive ixekizumab 160mg (starting dose) followed by every 4 Maintenance dosing period: Randomised to: Placebo: placebo SC every 4 weeks for 48 Dosing regimen 2: every 4 weeks for 48 Dosing regimen 3: every 12 weeks for 48 Non-responders (spga >1) at week 12 and patients who relapsed on every 4 Induction plus maintenance treatment period up to 60 Arm 2: ixekizumab 160mg SC at week 0, then ixekizumab 80mg once every four At week 12 patients are assigned to dosing regimen 2. Arm 3: etanercept 50mg SC twice weekly for 12 At week 12, patients are assigned to dosing regimen 2. Placebo: placebo for ixekizumab SC at week 0, then once every two weeks for 12 Placebo for etanercept SC twice weekly for 12 At week 12, patients are assigned to dosing regimen 2. Long term extension period from week 12 up to week 264. Dosing regimen 2: ixekizumab 80mg every 4 Active treatment period 264 6
7 Long-term extension period up to 264 Long-term extension period up to 264 Primary PASI, spga. PASI, spga. PASI, spga outcome/s Secondary outcome/s Quality of life d. Quality of life. Quality of life. Key results For patients treated with ixekizumab either every four weeks or every two weeks, 78-90% achieved at least a 75% reduction in PASI score (PASI 75) at 12 Additionally, 31-41% of these patients achieved PASI 100, or clear skin, at week 12. For comparison 5-7% of patients treated with etanercept in the NCT and NCT studies achieved PASI 100. Adverse effects (AEs) Expected reporting date The most frequently reported AEs (more than 5% across all three studies) were nasopharyngitis and injection site reaction. Most injection site reactions were mild, and most patients who experienced an injection site reaction continued treatment with ixekizumab. Study completion date reported as Apr Study completion date reported as Dec Study completion date reported as Feb Trial Sponsor Status Source of information Location Design Participants Schedule Follow-up Primary outcome/s Secondary outcome/s Key results NCT , 12060, I1F-MC-RHAJ; ixekizumab vs placebo; phase II. Eli Lilly and Company. Ongoing and published. Trial registry 23, publication 24. USA and Denmark. Randomised, placebo-controlled. n=142; aged 18 years and older; plaque psoriasis (at least 10% of body surface area); chronic; moderate to severe; spga score of at least 3 at screening and at randomisation; candidate for systemic therapy. Participants must have completed treatment period part A before starting part B. Part A Randomised to ixekizumab 10mg, 25mg, 75mg, 150mg or placebo SC on weeks 0, 2, 4, 8, 12 and 16. Part B Participants receive every 4 weeks until week 236. Active treatment period up to 264 PASI 75. spga score up to 240 weeks, AEs, Hospital Anxiety and Depression Scale (HADS), 16-item Quick Inventory of Depressive Symptoms-Self Rated (QIDS-SR16), Patient global assessment (PatGA), pain Visual Analog Scale (VAS), Medical Outcomes Study Sleep Scale (MOS-S), Psoriasis Medical Care Resource Utilization (PMRU), Work Productivity and Activity Impairment Questionnaire (WPAIQ), medical outcomes study Short Form-36 (SF-36), Nail Psoriasis Severity Index (NAPSI) in participants with nail psoriasis, Scalp Psoriasis Severity Index (SPSI) in participants with scalp psoriasis, Palmoplantar Psoriasis Severity Index (PPSI) in participants with palmoplantar psoriasis, PASI score at week 240, Dermatology Life Quality Index (DLQI), PASI-75 at week 32, spga score of 0-1 with at least a 2 point improvement at week 32. For ixekizumab 10mg, 25mg, 75mg, 150mg vs placebo respectively (± standard deviation, p values vs placebo): d Measured through patient reported outcomes. 7
8 Adverse effects (AEs) Expected reporting date PASI 75 score, 29%, 77%, 83%, 82% vs 8%; PASI 90, 18%, 50%, 59%, 71% vs 0%; PASI 100, 0%, 17%, 38%, 39% vs 0; spga score (0 or 1), 25%, 70%, 72%, 71% vs 8%; spga score (0), 7%, 20% (p<0.05), 38% 001) vs 0. The most common adverse events were nasopharyngitis, upper respiratory infection, injection site reaction, and headache. Study completion date reported as Jul ESTIMATED COST and IMPACT COST The cost of ixekizumab is not yet known. The costs of other selected biological therapies for psoriasis are detailed below Drug Dose Unit cost Annual cost Adalimumab Initially 80mg SC, then 40mg on (40mg, 9,295. (Humira) alternate weeks, one week after initial dose. prefilled syringe). Etanercept 25mg SC twice weekly or 50mg (25mg, prefilled 9,295. (Enbrel) Infliximab (Remicade) Ustekinumab (Stelara) once weekly. 5mg/kg IV repeated 2 weeks and 6 weeks after initial dose and then every 8 Initially 45mg SC, then 45mg 4 weeks after initial dose, then 45mg every 12 syringe) (100mg, vial). 10,910 (following loading doses and based on average 6.5 doses per year). 2,147 (45mg, prefilled syringe). 12,882. IMPACT - SPECULATIVE Impact on Patients and Carers Reduced mortality/increased length of survival Other: Impact on quality of life of families/carers and patients, including social wellbeing and education. Reduced symptoms or disability No impact identified Impact on Health and Social Care Services Increased use of existing services Re-organisation of existing services Other: Decreased use of existing services Need for new services None identified 8
9 Impact on Costs and Other Resource Use Increased drug treatment costs Other increase in costs: Other: uncertain unit cost compared to existing treatments, expert opinion suggests that indirect costs such as return to employment are also an important factor to consider e. Other Issues Clinical uncertainty or other research question identified: expert opinion implies that an important question to consider with these biological therapies is whether there are biomarkers (co-diagnostics) that can identify patients who are likely to be responders to these drugs based on modes of action. There is preliminary data that this concept may be real and it is therefore an important question for trials to address in the future maybe in drug development where there is adequate power to obtain good data e. Reduced drug treatment costs Other reduction in costs: None identified None identified REFERENCES 1 ClinicalTrials.gov. A multicentre study with a randomised, double-blind, placebo-controlled induction dosing period followed by a randomised maintenance dosing period and a long-term extension period to evaluate the efficacy and safety of LY in patients with moderate-tosevere plaque psoriasis. Accessed 17 March American Academy of Dermatology working group. Guidelines for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology 2008;58: Patient.co.uk. Psoriasis. November Accessed 17 March Psoriasis Association. About Psoriasis. March Accessed 17 March National Institute for Health and Clinical Excellence. The assessment and management of psoriasis. Clinical Guideline CG153. Manchester: NICE; October Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the national psoriasis foundation survey data PLOS ONE 2012;7(12):e NIHR Horizon Scanning Centre. Brodalumab for moderate to severe plaque psoriasis. University of Birmingham, May National Institute for Health and Care Excellence. Apremilast for treating moderate to severe plaque psoriasis. Final scope. London: NICE; October Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults. National clinical guideline 121. Edinburgh: SIGN; October NIHR Horizon Scanning Centre. Apremilast for psoriasis. University of Birmingham, January National Institute for Health and Care Excellence. Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology. Commissioning guide: Implementing NICE guidance. November 2012 (update). e Expert personal communication. 9
10 12 Health & Social Care Information Centre. Hospital episode statistics for England. Inpatient statistics, Office for National Statistics. Mortality statistics: deaths registered in England and Wales (Series DR) British Association of Dermatologists & Primary Care Dermatology Society. Recommendations for the initial management of psoriasis. October PCDS%20Psoriasis%20reviewed% pdf Accessed 12 October Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis British Journal of Dermatology 2009;161(5): NIHR Horizon Scanning Centre. Dimethyl fumarate for plaque psoriasis. University of Birmingham, November Hsu S, Papp KA, Lebwohl MG et al. Consensus guidelines for the management of plaque psoriasis. Archives of Dermatology 2012;148(1): Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis British Journal of Dermatology 2009;161(5): National Institute for Health and Care Excellence. Psoriasis. Final scope. London: NICE; December Eli Lilly and Company. Lilly s ixekizumab superior to etanercept in placebo in phase 3 psoriasis studies. August ClinicalTrials.gov. A multicentre, randomised, double-blind, placebo-controlled study comparing the efficacy and safety of LY to etanercept and placebo in patients with moderate-tosevere plaque psoriasis. Accessed 17 March ClinicalTrials.gov. A 12-week multicentre, randomised, double-blind, placebo-controlled study comparing the efficacy and safety of LY to etanercept and placebo in patients with moderate to severe plaque psoriasis with a long-term extension period. Accessed 17 March ClinicalTrials.gov. A dose-ranging and efficacy study of LY (an anti-il-17 antibody) in patients with moderate-to-severe psoriasis. Accessed 17 March Leonardi C, Matherson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. The New England Journal of Medicine 2012;366(13): National Institute for Health and Care Excellence. Adalimumab, etanercept and infliximab for the treatment of psoriatic arthritis: NICE; August The Royal Pharmaceutical Society. British National Formulary. BNF
Horizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationHorizon Scanning Centre May Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524
Horizon Scanning Centre May 2014 Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524 This briefing is based on information available at the time of research and a limited literature
More informationHorizon Scanning Centre January Apremilast for psoriasis SUMMARY NIHR HSC ID: 2652
Horizon Scanning Centre January 2013 Apremilast for psoriasis SUMMARY NIHR HSC ID: 2652 This briefing is based on information available at the time of research and a limited literature search. It is not
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationRisankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis
NIHR Innovation Observatory Evidence Briefing: November 2017 Risankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis NIHRIO (HSRIC) ID: 9708 NICE ID: 9191 LAY SUMMARY Plaque
More informationCertolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Dimethyl fumarate for treating moderate to severe Draft scope (pre-referral) Draft remit/appraisal objective To appraise
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationSingle Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis
Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psoriasis: the management of psoriasis 1.1 Short title Psoriasis 2 The remit The Department of Health has asked NICE: 'to produce
More informationixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd.
ixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd. 10 March 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442
Ixekizumab for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442 NICE 2017. All rights reserved. Subject to Notice of rights
More informationHorizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716
Horizon Scanning Centre January 2013 Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 This briefing is based on information available at the time of research and a limited literature search.
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION IXEKIZUMAB (Taltz Eli Lilly Canada Inc.) Indication: Moderate to Severe Plaque Psoriasis Recommendation: The CADTH Canadian Drug Expert Committee
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationEli Lilly and Company
Eli Lilly and Company Ixekizumab Phase 2 Psoriasis Data Investment Community Discussion April 10, 2012 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationInfliximab (Remicade) for paediatric ulcerative colitis - second line
Infliximab (Remicade) for paediatric ulcerative colitis - second line September 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationKEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.
KEY MESSAGES Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that affects primarily the skin and joints. Psoriasis Vulgaris is characterised by well-demarcated
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta368
Apremilast for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta368 NICE 2015. All rights reserved. Contents 1 Guidance...
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationUstekinumab for the treatment of moderate to severe psoriasis
DOI: 10.3310/hta13suppl3/10 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Ustekinumab for the treatment of moderate to severe psoriasis E Gospodarevskaya, J Picot, K Cooper, E Loveman* and A Takeda
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340
Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationBotulinum toxin A (Dysport) for hyperhidrosis of the axillae
April 2016 Horizon Scanning Research & Intelligence Centre Botulinum toxin A (Dysport) for hyperhidrosis of the axillae LAY SUMMARY This briefing is based on information available at the time of research
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationHorizon Scanning Centre November Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects
Horizon Scanning Centre November 2014 Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects SUMMARY NIHR HSC ID: 8515 This briefing is based on information
More informationTechnology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people Technology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455 NICE 2017. All rights
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationUSTEKINUMAB. London New Drugs Group APC/DTC Briefing Document. May 2009
Page 1 London New Drugs Group APC/DTC Briefing Document USTEKINUMAB Contents Summary 1 Background 4 Clinical efficacy 5 Cost implications 9 Reference list 10 Appendices 11 Produced for the London New Drugs
More informationBackground AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION
JULY 2018 Background PLAQUE PSORIASIS Plaque psoriasis is a common disease affecting 3% of the US population that causes itchy, red, scaly, raised lesions on the skin, most commonly on the elbows, knees,
More informationFinal Appraisal Report. Etanercept (Enbrel. Pfizer Limited. Advice No: 0210 March Recommendation of AWMSG
Final Appraisal Report Etanercept (Enbrel ) Pfizer Limited Advice No: 0210 March 2010 Recommendation of AWMSG Etanercept (Enbrel ) is not recommended for use within NHS Wales for the treatment of chronic
More informationIxekizumab for treating moderate to severe plaque psoriasis [ID904]
Thank you for agreeing to make a submission on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Single Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Single Technology Appraisal Apremilast for treating moderate to severe plaque psoriasis ID679 Consultee and commentator comment form Please use
More informationBrodalumab for treating moderate to severe plaque psoriasis [ID878]
Brodalumab for treating moderate to severe plaque psoriasis [ID878] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique
More informationustekinumab (Stelara )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationPsoriasis. Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid
Psoriasis Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid PSORIASIS Psoriasis News. Topical treatment Calcipotriene/Betamethasone Dipropionate (Cal/BD) foam: In the real-world, Cal/BD
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationdimethyl fumarate 30mg and 120mg gastro-resistant tablets (Skilarence ) SMC No 1313/18 Almirall Limited
dimethyl fumarate 30mg and 120mg gastro-resistant tablets (Skilarence ) SMC No 1313/18 Almirall Limited 9 March 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationHorizon Scanning Centre March Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468
Horizon Scanning Centre March 2014 Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468 This briefing is based on information available at the time
More informationA systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C
A systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C Authors' objectives To compare the effectiveness of currently available treatments
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2104-4 Program Prior Authorization/Medical Necessity Medication Taltz (ixekizumab) P&T Approval Date 8/2016, 5/2017, 2/2018 Effective
More informationThe role of current biologic therapies in psoriasis
: An Update on and IL-17 Inhibitors Joanna Dong, BA; Gary Goldenberg, MD PRACTICE POINTS The newest biologics for treatment of moderate to severe plaque psoriasis are and IL-17 inhibitors with unprecedented
More informationGuselkumab for treating moderate to severe plaque psoriasis [ID1075]
Guselkumab for treating moderate to severe plaque psoriasis [ID1075] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationAR101 peanut allergy immunotherapy for adult and paediatric patients
AR101 peanut allergy immunotherapy for adult and paediatric patients NIHRIO (HSRIC) ID: 11815 NIHR Innovation Observatory Evidence Briefing: May 2017 NICE ID: 8773 LAY SUMMARY Food allergy occurs when
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationPediatric Use: Safety and effectiveness of Ustekinumab (STELARA ) in pediatric patients have not been evaluated.
Original Issue Date (Created): January 1, 2010 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 I. POLICY Preauthorization Requirements for Ustekinumab (STELARA ) Note:
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs
More informationKTE-C19 for relapsed or refractory mantle cell lymphoma
NIHR Innovation Observatory Evidence Briefing: July 2017 KTE-C19 for relapsed or refractory mantle cell lymphoma NIHRIO (HSRIC) ID: 11846 NICE ID: 9122 LAY SUMMARY Mantle cell lymphoma is an uncommon type
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:
Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationCOSENTYX (secukinumab)
COSENTYX (secukinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationTargeted Immunomodulators for the Treatment of Moderate-to- Severe Plaque Psoriasis: Effectiveness and Value
Targeted Immunomodulators for the Treatment of Moderate-to- Severe Plaque Psoriasis: Effectiveness and Value Condition Update Final Background and Scope January 9, 2018 Background Psoriasis is a common
More informationrhngf for neurotrophic keratitis first line
September 2015 Horizon Scanning Research & Intelligence Centre rhngf for neurotrophic keratitis first line LAY SUMMARY This briefing is based on information available at the time of research and a limited
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationPSORIASIS BEST PRACTICE IN MANAGEMENT
PSORIASIS BEST PRACTICE IN MANAGEMENT Objectives Discuss pathology of psoriasis Review types of psoriasis Review triggers and factors affecting disease severity Common comorbidity review Review first and
More informationHorizon Scanning Centre July Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line
Horizon Scanning Centre July 2014 Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line SUMMARY NIHR HSC ID: 2635 This briefing is based on information available
More informationDetails of UNCOVER-2 and UNCOVER-3 Study Results Published in The Lancet
June 10, 2015 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Refer to: Immediately Tim Coulom; tim.coulom@lilly.com; 317-771-2241
More informationDERMATOLOGY. The Changing Landscape of Psoriasis Treatment ABSTRACT
WHITE PAPER PRESENTED BY PREMIER RESEARCH The Changing Landscape of Psoriasis Treatment ABSTRACT Over the past two decades, biologic therapies have revolutionized the treatment of psoriasis, with more
More informationapremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.
apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. 08 May 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationHorizon Scanning Centre July Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711
Horizon Scanning Centre July 2014 Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711 This briefing is based on information available at the time of research and a limited
More informationEtanercept: a new option in paediatric plaque psoriasis
: a new option in paediatric plaque psoriasis Steve Chaplin MSc, MRPharmS, Medical Writer, Dr David Atherton MA, MB, BChir, FRCP, Honorary Consultant in Paediatric Dermatology, Great Ormond Street Hospital
More informationPsoriasis. Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement
Psoriasis Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement Copyright 2017 by Sea Courses Inc. All rights reserved. No part
More informationUSTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE
Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)
More informationEtanercept and efalizumab for the treatment of adults with psoriasis. NICE technology appraisal guidance 103. Issue date: July 2006
Issue date: July 2006 Review date: deferred until 2010 Etanercept and efalizumab for the treatment of adults with psoriasis NICE technology appraisal guidance 103 NICE technology appraisal guidance 103
More informationCurrent treatment options in the management of psoriasis
Drug review Current treatment options in the management of psoriasis Eleanor Higgins MB BCh, BAO, MRCPI and Trevor Markham MD, BAO, MRCPI SPL is a common chronic condition and treatment choice primarily
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationA Patient s Guide to. Treatments for Psoriatic Arthritis
A Patient s Guide to Treatments for Psoriatic Arthritis Who should read this guide? This guide is aimed at people with psoriatic arthritis (abbreviated as PsA), or those who care for a person with this
More informationClinical Trial Report Synopsis
Clinical Trial Report Synopsis A phase 2a, proof of concept trial, testing twice daily application of LEO 124249 ointment 30 mg/g in the treatment of mild to moderate inverse psoriasis Design of trial:
More informationTopical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar
Topical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar Dr. Steven Feldman 1 Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationPsoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
More informationPsoriasis: Therapeutic goals
Psoriasis: Therapeutic goals I want to die 50 45 impetiginization infliximab 600 40 35 30 400 25 20 15 200 10 5 0 22-ene 21-feb 23-mar 22-abr 22- may Efalizumab 6 doses: flare + REBOUND CSA 3 21-jun 21-jul
More informationAUSTRALIAN PRODUCT INFORMATION
AUSTRALIAN PRODUCT INFORMATION This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationResearch Developments in Psoriasis Treatment A CME Activity
Overview Research Developments in Psoriasis Treatment A CME Activity Mark Lebwohl, MD, Waldman Chair of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, provides his perspectives
More informationTicagrelor (Brilique) for peripheral arterial disease
July 2016 Horizon Scanning Research & Intelligence Centre Ticagrelor (Brilique) for peripheral arterial disease LAY SUMMARY This briefing is based on information available at the time of research and a
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTechnology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta199
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta199 NICE 2018. All rights reserved. Subject
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #410: Psoriasis: Clinical Response to Systemic Medications National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes Meaningful Measure Area: Management of Chronic
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More information